Inari Medical (NARI)

Executive Summary

Inari Medical is a commercial-stage medical device company focused on transforming the treatment of venous thromboembolism (VTE) through its minimally invasive, lytic-free mechanical thrombectomy platforms. Its flagship products, the FlowTriever and ClotTriever systems, address pulmonary embolism (PE) and deep vein thrombosis (DVT), respectively, offering a single-session alternative to traditional therapies. The company has established a strong clinical evidence base and a growing installed base in the U.S., driving revenue growth and market share gains in the large and underserved VTE market. Inari's competitive advantage lies in its proprietary technology that avoids the use of thrombolytics, reducing bleeding risk and enabling rapid, effective clot removal. With a direct sales force and expanding product portfolio, the company is well-positioned to capture further upside from guideline inclusions, new indication approvals, and international expansion. Looking ahead, Inari Medical is poised to benefit from several upcoming catalysts. The company is pursuing broader labeling for its existing devices, including a potential FDA approval for use in submassive PE, which could significantly expand the treatable patient population. Additionally, clinical trial readouts for next-generation devices or novel applications (e.g., pulmonary embolism in intermediate-risk patients) are expected to strengthen the evidence base and support market penetration. Finally, positive coverage decisions from CMS and inclusion in professional society guidelines would further drive adoption. Given its strong product portfolio, robust clinical data, and large addressable market, Inari Medical presents an attractive opportunity with significant growth runway.

Upcoming Catalysts (preview)

• Q2 2026FDA approval for FlowTriever in submassive pulmonary embolism80% success
• H2 2026Pivotal trial results for next-generation thrombectomy device70% success
• Q1 2027Medicare coverage determination for mechanical thrombectomy in VTE65% success